Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705).

ABSTRACT

BACKGROUND: Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2-29.1%). Unfortunately, there is no specific cure or vaccine for SFTS. METHODS: In this open-label study, two patients with SFTS were treated with favipiravir, a new antiviral drug. RESULTS: Patients had a sustainable virologic, immunologic and symptomatic recovery. CONCLUSIONS: Favipiravir may be a prosiming drug for the treatment of SFTS.